{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-25-000054","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.607811+00:00","generated_at":"2026-05-17T06:12:44.960044+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Amphastar enters $2.8M R&D agreement with related-party Hanxin for AMP-107 cell banks","bullets":["Agreement with Nanjing Hanxin to develop Recombinant Peptide Research Cell Banks (RCBs) for product candidate AMP-107.","Total cost not to exceed ~$2.8M; initial payment ~$0.3M; payments in Chinese yuan.","Hanxin majority-owned by CEO Jack Zhang, Chairman Mary Luo, and family; approved by independent audit committee.","Term of three years; all title to RCBs and related IP will belong to Amphastar."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-25-000054","json":"https://secwatch.observer/filing/0001297184-25-000054.json","markdown":"https://secwatch.observer/filing/0001297184-25-000054.md","text":"https://secwatch.observer/filing/0001297184-25-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000054/0001297184-25-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000054/amph-20250915x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:12:44.960044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}